CRH Medical (CRHM) Earns Buy Rating from TD Securities

Share on StockTwits

TD Securities reaffirmed their buy rating on shares of CRH Medical (NYSEAMERICAN:CRHM) in a research note released on Tuesday morning.

Separately, Zacks Investment Research raised shares of CRH Medical from a sell rating to a hold rating in a report on Monday, November 26th.

CRH Medical stock opened at $3.11 on Tuesday. CRH Medical has a fifty-two week low of $2.40 and a fifty-two week high of $4.50.

Several institutional investors have recently added to or reduced their stakes in CRHM. ClariVest Asset Management LLC bought a new position in shares of CRH Medical in the third quarter worth $154,000. Acadian Asset Management LLC bought a new position in shares of CRH Medical in the third quarter worth $354,000. Wedge Capital Management L L P NC bought a new position in shares of CRH Medical in the third quarter worth $373,000. Ativo Capital Management LLC increased its holdings in shares of CRH Medical by 7.1% in the third quarter. Ativo Capital Management LLC now owns 300,079 shares of the company’s stock worth $1,185,000 after purchasing an additional 20,002 shares during the period. Finally, Renaissance Technologies LLC grew its position in CRH Medical by 46.0% in the second quarter. Renaissance Technologies LLC now owns 383,600 shares of the company’s stock worth $1,189,000 after acquiring an additional 120,800 shares in the last quarter.

About CRH Medical

CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.

Read More: Day Trading – Risk Worth the Reward?

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply